Drug-Drug Interactions and Prescription Appropriateness in COVID-19 ICU Patients

"Drug-Drug Interactions and Prescription Appropriateness in COVID-19 ICU Patients in a Tertiary Care Hospitalâ??

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2022/09/045611

Enrollment

191

Registered

2022-09-16

Start date

Unknown

Completion date

Unknown

Last updated

2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: U071- COVID 19 virus identified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Case record of all adult patients with proven diagnosis of SARS-CoV-2 infection (a throat swab positive for viral nucleic acid) admitted to the COVID-19 ICU during the study period and treated with at least two drugs will be considered.

Exclusion criteria

Exclusion criteria: Patients transferred to other wards from ICU or discharged/death within 24hr of admission will be excluded.

Design outcomes

Primary

Measure	Time frame
To assess the frequency and severity of potential DDIs in COVID-19 ICU patientsTimepoint: March to July 2021	—

Secondary

Measure	Time frame
To evaluate PIMs in the subset of patients aged more than or equal to 65 yearsTimepoint: March to July 2021	—

Countries

India

Contacts

Public ContactSuraj B

ESIC Medical College and Hospital

drsurajpanchal@gmail.com8861083454

Outcome results